Ducaro Tablet 60/10/20 mg (Pimodipine, Amlodipine, Rosuvastatin)
Fimasartan Potassium Trihydrate Granules 150mg · Amlodipine Besylate 13.88mg +1 more
Tablet · Prescription medication · Combination
Boryung Co., Ltd.
MFDS item code 201907896 · Approved 2019.11.13
Treatment of hypertension; improvement of dyslipidemia; inhibition of atherosclerosis progression and prevention of cardiovascular disease
This medication is used for patients who need to take a combination of Pimodipine/Amlodipine and Rosuvastatin simultaneously. The Pimodipine/Amlodipine combination is applicable to patients with essential hypertension who have difficulty controlling blood pressure with monotherapy. Rosuvastatin is used as an adjunct treatment for patients with primary hypercholesterolemia and combined dyslipidemia that cannot be controlled by diet and exercise. Additionally, it is prescribed as an adjunct to diet for patients with homozygous familial hypercholesterolemia or dysbetalipoproteinemia. This medication helps lower total cholesterol and LDL cholesterol levels, delays the progression of atherosclerosis, and reduces the risk of cardiovascular diseases, stroke, myocardial infarction, and vascular reintervention. Thus, it is used to improve cardiovascular health by managing both blood pressure and cholesterol.
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the fimasartan/amlodipine combination and rosuvastatin. Patients taking the fimasartan/amlodipine combination together with rosuvastatin as a single-ingredient product may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Before starting the fimasartan/amlodipine combination, it is recommended that the dose be adjusted using fimasartan. However, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy. ㆍ 30/10 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy or 30/5 mg. ㆍ 60/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy. ㆍ 60/10 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy or 60/5 mg. Elderly patients No initial dose adjustment is required in elderly patients aged 70 years or younger. In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a lower dose, and the dose should be increased gradually. Patients with renal impairment No dose adjustment is required in patients with mild ~ moderate renal impairment (creatinine clearance 30 ~ 80 mL/min). However, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 mg in this medicine. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment. This medicine should not be administered to patients with moderate ~ severe hepatic impairment. 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which provides adequate control in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients.
The safety and efficacy of this medicine have not been established in pediatric and adolescent patients aged 18 years or younger.
This medication can cause serious harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately upon confirmation of pregnancy. Patients with hypersensitivity to any component of this medication, pregnant women, nursing mothers, patients with severely impaired liver function, and patients with poor kidney function should not take this medication. Patients with low blood volume or salt depletion, those with impaired kidney function, the elderly, and patients with myasthenia gravis should use this medication with caution and must closely monitor their condition while on it. This drug may affect the liver and kidneys, so regular liver and kidney function tests should be done before and during treatment. If symptoms such as muscle pain or weakness, rash, itching, dizziness, nausea, or abdominal discomfort occur, consult a doctor immediately, especially since muscle-related symptoms may indicate serious side effects. This drug may interact with other medications; therefore, patients should inform their healthcare provider if they are taking any other drugs, especially potassium-sparing diuretics, lithium, non-steroidal anti-inflammatory drugs, or certain antibiotics or antifungals. Women of childbearing potential should use appropriate contraceptive methods while taking this drug, and nursing women should either avoid this medication or stop breastfeeding. The safety and efficacy of this medication have not been established in children or adolescents under 18 years of age; therefore, it is not recommended for this population. In case of an overdose, symptoms such as hypotension, arrhythmia, and severe vasodilation may occur; hence, do not exceed the prescribed dose and seek medical attention if adverse effects occur. During treatment, caution is necessary as dizziness may occur while driving or operating machinery. Store this medication in a safe place out of reach of children, and avoid transferring it to other containers.
Nausea
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to protect it from air and moisture, ideally at a temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's efficacy for an extended period.
Yellow round film-coated tablets
30 tablets/box [10 tablets/PTP*3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Fimasartan Potassium Trihydrate Granules 150mg · Amlodipine Besylate 13.88mg +1 more
Tablet · Prescription medication · Combination
Boryung Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 150mg · Amlodipine Besylate 6.94mg +1 more
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 75mg · Amlodipine Besylate 6.94mg +1 more
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 150mg · Amlodipine Besylate 6.94mg +1 more
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate Granules 75mg · Amlodipine Besylate 6.94mg +1 more
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.